Trial Profile
Exploratory clinical study for apatinib mesylate in the treatment of recurrent thymoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenoma; Liver metastases; Malignant thymoma; Thymoma
- Focus Therapeutic Use
- 17 Sep 2018 New trial record